ANN ARBOR, Mich., May 29 /PRNewswire/ -- NanoBio(R) Corporation, a
biopharmaceutical company focused on developing and commercializing novel
products for the prevention and treatment of infectious diseases, today
announced the appointment of David M. Stout to its Board of Directors. Mr.
Stout most recently served as President of Pharmaceutical Operations for
"We are pleased to welcome David to our Board of Directors and look
forward to benefiting from his guidance and contributions," said James R.
Baker Jr., M.D., chairman of NanoBio Corporation. "David's 30-plus years of
experience in all facets of the pharmaceutical industry -- including his
recent experience as head of global pharmaceutical operations for GSK, a
world leader in infectious diseases -- will be invaluable to NanoBio as we
approach the commercialization of our lead anti-infective and vaccine
NanoBio's lead products are topical lotions and mucosal vaccines to
combat a wide array of viruses, bacteria and fungi. They include topical
treatments for herpes labialis (cold sores), onychomycosis (nail fungus)
and bacterial skin infections (including MRSA), as well as mucosal vaccines
for seasonal and pandemic influenza, hepatitis B and RSV. The company's
nanoemulsion-based products have demonstrated potent antimicrobial effects
in several clinical trials, without safety concerns or systemic absorption.
The products use a physical mode of action rather than chemical synthesis
to disrupt pathogen membranes, rendering the emergence of drug resistance
"The platform technology upon which NanoBio's products are based
represents a truly novel approach to combating infections and provides a
rich pipeline of anti-infective products and vaccines for the future,"
Stout said. "Given the company's recent and very compelling clinical
results, I am particularly excited to be joining the company's board at
this time. I look forward to working with NanoBio's management in bringing
these new therapies and vaccines to the market."
In his most recent position as President of Pharmaceutical Operations
at GSK, Mr. Stout led all global commercial activities, global
manufacturing and all vaccine-related activities, including research and
development, as well as other executive functions. Additionally, Mr. Stout
directed the corporate pandemic flu preparedness program, an international
effort that supports governments, health authorities and company employees
around the world in planning to respond to a global influenza pandemic.
Prior to his tenure at GSK, Mr. Stout held executive leadership positions
at Glaxo Wellcome, SmithKline Beecham and Schering-Plough Corporation.
NanoBio(R) Corporation is a privately held biopharmaceutical company
focused on developing and commercializing anti-infective products and
mucosal vaccines derived from its patented NanoStat(TM) technology
platform. The company's lead product candidates are treatments for herpes
labialis (cold sores), onychomycosis (nail fungus) and mucosal vaccines for
influenza and hepatitis B. The company's headquarters and laboratory
facilities are located in Ann Arbor, Mich.
SOURCE NanoBio Corporation